Table 2 Treatment parameters at baseline (Mean ± SE)
From: A randomized trial of transdermal and oral estrogen therapy in adolescent girls with hypogonadism
Oral conjugated E2 | Oral 17β E2 | Transdermal 17β E2 | |
|---|---|---|---|
Estradiol (pg/mL) | 3.1 ± 1.1 | 1.2 ± 0.3 | 5.2 ± 3.5 |
Estrone (pg/mL) | 11.3 ± 4.2 | 5.1 ± 0.8 | 9.3 ± 2.4 |
Estrone Sulfate (ng/dL) | 18 ± 6.5 | 10 ± 1.8 | 11 ± 0.9 |
FSH (mIU/mL) | 86 ± 27.2 | 71 ± 18.3 | 76 ± 30.6 |
LH (mIU/mL) | 26 ± 10.3 | 13 ± 3 | 14 ± 5.6 |
SHBG (nmol/L) | 63 ± 22 | 52 ± 11 | 67 ± 13.4 |
HS-CRP (mg/L) | 1.5 ± 0.9 | 2.6 ± 2.1 | 1.5 ± 1.2 |
Fibrinogen Activity (mg/dL) | 305 ± 29.2 | 280 ± 25.3 | 291 ± 30.6 |
Antithrombin Activity (%) | 115 ± 4.4 | 125 ± 5 | 120 ± 4 |
Glucose (mg/dL) | 74 ± 2.7a | 85 ± 2.8 | 84 ± 1.7 |
Insulin (uIU/mL) | 7.2 ± 2 | 5.1 ± 1.3 | 4.5 ± 1 |
AST (U/L) | 39 ± 8.2 | 25 ± 2.2 | 25 ± 0.8 |
ALT (U/L) | 46 ± 18.7 | 22 ± 3.6 | 16 ± 2.1 |
Cholesterol (mg/dL) | 187 ± 15.3 | 168 ± 7.2 | 167 ± 11.1 |
Triglycerides (mg/dL) | 140 ± 21.8 | 76 ± 13.9 | 101 ± 16.3 |
HDL (mg/dL) | 49.3 ± 4 | 55 ± 6.2 | 49 ± 5.8 |
LDL (mg/dL) | 113 ± 16.1 | 94 ± 5.1 | 97 ± 7.9 |
Plasma Renin (ng/dL/h) | 192 ± 41.4 | 230 ± 71 | 229 ± 78.7 |
IGFBP-3 (mg/L) | 3.1 ± 0.5 | 3.9 ± 0.2 | 4 ± 0.6 |
IGF-1 (ng/mL) | 226 ± 50.2 | 361 ± 62 | 318 ± 84 |